The medicine is a cardioselective blocker of beta-1-adrenergic receptors. A major risk index for glaucomatous scotoma is an increased tension. When its rate is soaring, the eyes are more damaged. As a consequence, a visual field narrows. Betoptic reduces both increased and usual pressure, regardless of if it occurs with glaucoma, or not; the structure of its activity is connected with a decline in the performance of intraocular fluid. Betaxolol acts after half-an-hour, and the expected result is normally achieved after 2 hours after application.